Source link : https://www.newshealth.biz/health-news/novel-glp-1-glucagon-drug-promising-for-weight-loss/
ORLANDO — Novel dual GLP-1 and glucagon agonist pemvidutide reduced weight and lipids with somewhat less muscle loss than expected, the phase II MOMENTUM trial showed. Weight lost over 48 weeks ranged in a dose-dependent manner from 10.3% with the 1.2 mg weekly dose to 15.6% with the 2.4 mg weekly dose (P
Author : News Health
Publish date : 2024-06-24 17:08:29
Copyright for syndicated content belongs to the linked Source.
Categories